E!114244, Blue4Therapy, AcouSort
|Coordinator||AcouSort AB - AcouSort AB Medicon Village|
|Funding from Vinnova||SEK 3 108 500|
|Project duration||September 2020 - April 2023|
Purpose and goal
The use of ADRC (adipose derived regenerative cells) is a promising strategy for regenerative therapy. The number of BlueCells (CD31+ cells) present at low concentrations in ADRC samples has been shown to correlate positively with treatment efficacy. Within the project, a BlueSORT machine has been developed and manufactured that can separate BlueCells from ADRC samples using ultrasound. A cartridge for a single-use separation module has been developed and the machine together with the cartridge has been successfully tested with patient samples.
Expected results and effects
The isolation of ADRC from adipose tissue samples could be quadrupled after the optimization of the standard protocol. A method using ultrasound to separate BlueCells from ADRC samples has been developed and successfully tested with patient samples. Manufacturing of a BlueSORT machine with consumables, developed within the project, makes it possible to have a reliable and reproducible purification of BlueCells for research and clinical treatment. Further studies will demonstrate the effectiveness of purified BlueCells for use in regenerative therapy.
Planned approach and implementation
nterviews with relevant customers/users were performed in the beginning of the project to gather requirements related to performance, functionality, and safety of a BlueSORT platform. The outcome of the interviews was used as input and guidance for the different work packages. Close collaboration between the partners was kept during the project. A steering group was formed, and the project progress was discussed in regular consortium meetings.